Latest Intarcia Therapeutics Inc. Stories

2014-08-05 08:35:45

- Zalani joins Intarcia to drive the strategic and operational direction of Intarcia's Global Regulatory and Quality efforts with health authorities, partners and external stakeholders - BOSTON, Aug. 5, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today officially announced the appointment of Sunita Zalani, Ph.D., as Vice President and Global Head of Regulatory Affairs and Quality. In her new capacity, Dr. Zalani serves on the Leadership Team and reports directly to Chairman,...

2014-06-15 08:21:29

-- The average HbA1C reductions in patients treated with ITCA 650 for 6 months at the time of the interim analysis were -3.2%; patients at baseline had HbA1C levels between 10-12%. BOSTON, June 15, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74(th) Scientific Sessions of the American Diabetes Association (ADA) held in San Francisco that contained the first 6-month data from an ongoing open-label phase 3 trial...

2014-04-01 08:28:59

-Promising first interim phase 3 data for ITCA 650 in type 2 diabetes, combined with robust execution against key milestones and the addition of key talent BOSTON, April 1, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the completion of another landmark private round of equity financing for $200 million. Together with the $210 million round of equity and debt financing in November of 2012 the company is very strongly positioned for future milestones and launch...

2014-02-26 08:30:09

- Smith takes-on innovative CXO role to optimize customer experiences and consistently deliver the best possible outcomes for patients, payors and providers - BOSTON, Feb. 26, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today formally announced the appointment of Jay Smith as Head of Customer Experience & Outcomes (CXO), an officer level position for which there is no precedent or analogue in the Bio-Pharma industry. The role focuses on one of the highest priorities within...

2014-01-13 08:29:42

- Highlights will include first interim phase 3 data for ITCA 650, the Company's novel once or twice-yearly GLP-1 receptor agonist for type 2 diabetes. Data will show up to six months of treatment results from Intarcia's global Phase 3 clinical trial program known as FREEDOM - BOSTON, Jan. 13, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced that Chairman, President and CEO Kurt Graves will present a Company overview today at the J.P. Morgan 32nd Annual Healthcare...

Word of the Day
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.